Olgu Sunumu
BibTex RIS Kaynak Göster
Yıl 2021, , 97 - 99, 31.03.2021
https://doi.org/10.7197/cmj.890173

Öz

Kaynakça

  • 1- Gedikli, M. A., Tuzun, B., Aktas, A., Sayin, K., & Ataseven, H. (2021). Areclarithromycin, azithromycinandtheiranalogueseffective in thetreatment of COVID19?. Bratislavskelekarskelisty, 122(2), 101-110.
  • 2- Aktas, A., Tuzun, B., Taskin, A. H., Sayin, K. O. R. A. Y., & Ataseven, H. (2020). How do arbidolanditsanalogsinhibitthe SARS-CoV-2?. Bratislavskelekarskelisty, 121(10), 705-711.
  • 3- Aktaş, A.,Sener, K., Yılmaz, N., Tunç, M., & Yolcu, S. (2020). Is MeanPlatelet Volume UsefulforPredictingthePrognosis of COVID-19 DiagnosedPatients?. Age, 54(18,191), 18-191.
  • 4- Huzmeli, C., Candan, F., Bagci, G., Alaygut, D., Yilmaz, A., Gedikli, A., ... &Kayatas, M. (2017). Frequency of familialMediterraneanfever (MEFV) gene mutations in patientswithbiopsy-provenprimaryglomerulonephritis. Clinicalrheumatology, 36(11), 2589-2594.
  • 5- Becker, R. C. (2020). COVID-19-associated vasculitisandvasculopathy.
  • 6- Iba, T.,Connors, J. M., &Levy, J. H. (2020). Thecoagulopathy, endotheliopathy, andvasculitis of COVID-19. InflammationResearch, 1-9.

Case report, COVID-19 related vasculitis

Yıl 2021, , 97 - 99, 31.03.2021
https://doi.org/10.7197/cmj.890173

Öz

This disease, which is called COVID-19 disease due to the SARS COV2 virus, which emerged as a result of the mutation of the coronavirus in China in 2019, and caused significant morbidity and mortality all over the world due to the pandemic it created, has become the world's most important health problem. COVID-19 clinic emerges in a wide spectrum from mild viral infection to severe respiratory failure. COVID-19 is thought to be a syndrome that involves multiple organs and systems in various ways, especially endothelial damage.With this case, we wanted to emphasize that this virus is not only isolated in the respiratory system and should be kept in mind in today's conditions among the rare causes of vasculitis.

Kaynakça

  • 1- Gedikli, M. A., Tuzun, B., Aktas, A., Sayin, K., & Ataseven, H. (2021). Areclarithromycin, azithromycinandtheiranalogueseffective in thetreatment of COVID19?. Bratislavskelekarskelisty, 122(2), 101-110.
  • 2- Aktas, A., Tuzun, B., Taskin, A. H., Sayin, K. O. R. A. Y., & Ataseven, H. (2020). How do arbidolanditsanalogsinhibitthe SARS-CoV-2?. Bratislavskelekarskelisty, 121(10), 705-711.
  • 3- Aktaş, A.,Sener, K., Yılmaz, N., Tunç, M., & Yolcu, S. (2020). Is MeanPlatelet Volume UsefulforPredictingthePrognosis of COVID-19 DiagnosedPatients?. Age, 54(18,191), 18-191.
  • 4- Huzmeli, C., Candan, F., Bagci, G., Alaygut, D., Yilmaz, A., Gedikli, A., ... &Kayatas, M. (2017). Frequency of familialMediterraneanfever (MEFV) gene mutations in patientswithbiopsy-provenprimaryglomerulonephritis. Clinicalrheumatology, 36(11), 2589-2594.
  • 5- Becker, R. C. (2020). COVID-19-associated vasculitisandvasculopathy.
  • 6- Iba, T.,Connors, J. M., &Levy, J. H. (2020). Thecoagulopathy, endotheliopathy, andvasculitis of COVID-19. InflammationResearch, 1-9.
Toplam 6 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Case Reports
Yazarlar

İbrahim Karaduman 0000-0003-4639-7464

Yayımlanma Tarihi 31 Mart 2021
Kabul Tarihi 26 Mart 2021
Yayımlandığı Sayı Yıl 2021

Kaynak Göster

AMA Karaduman İ. Case report, COVID-19 related vasculitis. CMJ. Mart 2021;43(1):97-99. doi:10.7197/cmj.890173